Skip to content

Fostering Diversity & Inclusion: Embracing Differences at Scailyte

Highlighting Our Commitment to Diversity & Inclusion

A Diverse and Inclusive Team: Celebrating Differences at Scailyte

Highlighting Our Commitment to Diversity and Inclusion

🌍 At Scailyte, we take great pride in our commitment to Environmental, Social, and Governance (ESG) principles. Today, we want to highlight our strong focus on Diversity and Inclusion, particularly in terms of nationality and gender pay. 🌈🤝

With a team of 22 people, we have fostered a diverse and inclusive environment where everyone’s unique backgrounds and perspectives are celebrated. We firmly believe that diversity fuels innovation and drives success. 💡🚀

Gender diversity is a top priority for us, and we are proud to say that 50% of our full team consists of talented and inspiring women. But it doesn’t stop there—when it comes to leadership positions, 2 of the 3 C-level positions are held by exceptional women. 💼👩‍💼

Our diversity extends beyond gender. We are a team comprised of individuals from various nationalities, representing the rich tapestry of cultures around the globe. 🌎✨ Here is a snapshot of the nationalities that make up our Scailyte family:

🇧🇬 Bulgaria

🇨🇭 Switzerland

🇺🇸 USA

🇫🇷 France

🇮🇹 Italy

🇵🇹 Portugal

🇵🇱 Poland

🇩🇪 Germany

🇵🇰 Pakistan

🇮🇳 India

🇧🇩 Bangladesh

🏴󠁧󠁢󠁷󠁬󠁳󠁿 Wales

🇳🇿 New Zealand

🇭🇷 Croatia

By embracing such a diverse range of backgrounds, experiences, and perspectives, we foster an inclusive environment that values and respects everyone’s contributions. Together, we push the boundaries of innovation and create groundbreaking solutions for the future. 💪💫

At Scailyte, we firmly believe that true success is achieved through the collective power of a diverse and inclusive workforce. We remain committed to nurturing a culture that promotes equality, fosters innovation, and empowers every individual to thrive. 🌟🤝

 

About Scailyte

Scailyte is an ETH Zürich spin-off with a best-in-class artificial intelligence platform for the discovery of complex disease patterns from single-cell data. Our solution provides unprecedented insight into the disease and patients’ biology and enables the discovery of new clinically-relevant biomarker signatures by uncovering human’s hidden “single-cell” secrets. 

Scailyte’s proprietary best-in-class data analysis platform ScaiVision™ associates multimodal single-cell datasets (RNA-/TCR-/BCR-seq, proteomics, etc.) with clinical endpoints, such as disease diagnosis, progression, severity, treatment response, and toxicity response to identify ultra-sensitive biomarker signatures and cell functionality states. The performance and clinically-relevant applications of Scailyte’s platform ScaiVision have been demonstrated in well established CAR-T cell therapies and various clinical projects in Oncology and Immunology.

For more information, visit www.scailyte.com and connect on social media @LinkedIn and @Twitter.

ScailyteTM and ScaiVisionTM are registered trademarks proprietary to Scailyte AG.

Recent News

Scailyte Strengthens Its Leadership

Scailyte appoints Tim Foley as Chief Business Officer, Jean-Pierre Rosat as Executive Chair, and Dar...

Read more

Recent News

Scailyte Announces Virginia Savova, PhD as a Strategic and Scientific Advisor

Scailyte Announces Virginia Savova, PhD as a Strategic and Scientific Advisor. Dr. Savova brings str...

Read more

Recent News

Scailyte at BIO International Convention 2024

We are thrilled to attend the Bio International Convention 2024 in San Diego on June 3-6 where busin...

Read more

Recent News

Inside Scailyte - Episode 10: Meet Dennis Göhlsdorf

In our latest episode of "Inside Scailyte," we're excited to introduce you to Dennis Göhlsdorf, our...

Read more

Recent News

Precision Med TRI-CON 2024

Join us for our presentation on "Enabling Precision Medicine by Combining Single-Cell Multi-Omics Da...

Read more

Recent News

Inside Scailyte - Episode 9: Meet Shaoline Sheppard

In the latest episode of "Inside Scailyte," we're thrilled to introduce you to Shaoline Sheppard, ou...

Read more

Recent News

NextGen Omics US 2024

Scailyte is headed to NextGen Omics US 2024 in Boston, MA on March 21-22. Join us as we showcase our...

Read more

Recent News

AI-driven single-cell data analysis identifies a cell signature predictive of neurotoxicity and clinical response in CAR-T cell therapy of DLBCL

In our latest white paper, "AI-driven single-cell data analysis identifies a cell signature predicti...

Read more

Recent News

01 /04

Scailyte Strengthens Its Leadership

Scailyte appoints Tim Foley as Chief Business Officer, Jean-Pierre Rosat as Executive Chair, and Dar...

Read more

Scailyte Announces Virginia Savova, PhD as a Strategic and Scientific Advisor

Scailyte Announces Virginia Savova, PhD as a Strategic and Scientific Advisor. Dr. Savova brings str...

Read more

Recent News

02 /04

Scailyte at BIO International Convention 2024

We are thrilled to attend the Bio International Convention 2024 in San Diego on June 3-6 where busin...

Read more

Inside Scailyte - Episode 10: Meet Dennis Göhlsdorf

In our latest episode of "Inside Scailyte," we're excited to introduce you to Dennis Göhlsdorf, our...

Read more

Recent News

03 /04

Precision Med TRI-CON 2024

Join us for our presentation on "Enabling Precision Medicine by Combining Single-Cell Multi-Omics Da...

Read more

Inside Scailyte - Episode 9: Meet Shaoline Sheppard

In the latest episode of "Inside Scailyte," we're thrilled to introduce you to Shaoline Sheppard, ou...

Read more

Recent News

04 /04

NextGen Omics US 2024

Scailyte is headed to NextGen Omics US 2024 in Boston, MA on March 21-22. Join us as we showcase our...

Read more

AI-driven single-cell data analysis identifies a cell signature predictive of neurotoxicity and clinical response in CAR-T cell therapy of DLBCL

In our latest white paper, "AI-driven single-cell data analysis identifies a cell signature predicti...

Read more

Recent News